• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转移性乳腺癌亚型的肿瘤标志物:升高频率与预后的相关性。

Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome.

机构信息

Department of Medical Oncology, British Columbia Cancer Agency, Vancouver Cancer Center, Vancouver, Canada.

出版信息

Ann Oncol. 2012 Feb;23(2):338-45. doi: 10.1093/annonc/mdr154. Epub 2011 May 4.

DOI:10.1093/annonc/mdr154
PMID:21543625
Abstract

BACKGROUND

Little is known about the correlations between tumor markers (TMs), breast cancer subtypes, site(s) of metastasis and prognosis.

METHODS

Women diagnosed with metastatic breast cancer were included. Breast cancer subtypes were defined as LuminalA, LuminalB, LuminalHer2, Her2, Basal and non-Basal triple negative (TN). Levels of elevation of TM values [cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) and cancer antigen 125 (CA 125)] among the subtypes were analyzed. Site(s) of metastasis and outcomes were captured.

RESULTS

Eight hundred and ten patients were included. Luminal subtypes were associated with an elevation in at least one TM: 90.8% of LuminalHer2+, 90% of LuminalB and 88.6% of LuminalA. TMs were less frequently elevated in Basal (74.1%) and non-Basal TN (71.4%) cases (P < 0.001). CA 15-3 was the most frequently elevated TM. The incidence of TM elevation did not differ between patients with solitary versus multiple metastatic sites. Breast cancer-specific survival (BCSS) was significantly worse for patients with elevated TMs (P = 0.001).

CONCLUSIONS

TM elevation of CA 15-3, CEA and/or CA 125 was documented in the majority of patients with metastatic breast cancer with CA 15-3 occurring most commonly. Luminal subtypes expressed elevated TMs significantly more frequently compared with the non-Luminal groups. TM elevation was not different between the different sites of metastasis. Overall, elevated TMs predicted a worse BCSS.

摘要

背景

关于肿瘤标志物(TMs)、乳腺癌亚型、转移部位和预后之间的相关性知之甚少。

方法

纳入诊断为转移性乳腺癌的女性患者。乳腺癌亚型定义为 LuminalA、LuminalB、LuminalHer2、Her2、基底和非基底三阴性(TN)。分析了各亚型 TMs 值升高的情况[癌抗原 15-3(CA 15-3)、癌胚抗原(CEA)和癌抗原 125(CA 125)]。记录转移部位和结局。

结果

共纳入 810 例患者。Luminal 亚型与至少一种 TM 升高相关:LuminalHer2+ 为 90.8%、LuminalB 为 90%、LuminalA 为 88.6%。基底型(74.1%)和非基底型 TN(71.4%)病例中 TMs 升高的频率较低(P<0.001)。CA 15-3 是最常升高的 TM。有单一或多个转移部位的患者 TM 升高的发生率无差异。TM 升高的患者乳腺癌特异性生存率(BCSS)显著更差(P=0.001)。

结论

大多数转移性乳腺癌患者的 CA 15-3、CEA 和/或 CA 125 升高,最常见的是 CA 15-3。与非 Luminal 组相比,Luminal 亚型表达 TMs 升高的频率显著更高。不同转移部位的 TM 升高无差异。总体而言,TM 升高预示着 BCSS 更差。

相似文献

1
Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome.转移性乳腺癌亚型的肿瘤标志物:升高频率与预后的相关性。
Ann Oncol. 2012 Feb;23(2):338-45. doi: 10.1093/annonc/mdr154. Epub 2011 May 4.
2
Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study.肿瘤标志物CA15-3、CA125、癌胚抗原与分子亚型的乳腺癌生存率:一项队列研究
Breast Cancer. 2020 Jul;27(4):621-630. doi: 10.1007/s12282-020-01058-3. Epub 2020 Feb 10.
3
Preoperative CA 15-3 levels predict the prognosis of nonmetastatic luminal A breast cancer.术前CA 15-3水平可预测非转移性腔面A型乳腺癌的预后。
J Surg Res. 2014 Jun 1;189(1):48-56. doi: 10.1016/j.jss.2014.02.048. Epub 2014 Mar 2.
4
The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.血清肿瘤标志物癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、糖类抗原125(CA125)、糖类抗原15-3(CA15-3)及组织多肽特异性抗原(TPS)在转移性乳腺癌中的诊断价值
Clin Chim Acta. 2017 Jul;470:51-55. doi: 10.1016/j.cca.2017.04.023. Epub 2017 Apr 27.
5
Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.血清肿瘤标志物癌胚抗原(CEA)和糖类抗原15-3(CA15-3)水平升高是乳腺癌不同分子亚型的预后参数。
PLoS One. 2015 Jul 24;10(7):e0133830. doi: 10.1371/journal.pone.0133830. eCollection 2015.
6
The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry.术前肿瘤标志物(CEA、CA15-3)升高对乳腺癌患者预后的意义:来自韩国乳腺癌学会注册中心的数据。
Breast Cancer Res Treat. 2019 Oct;177(3):669-678. doi: 10.1007/s10549-019-05357-y. Epub 2019 Jul 16.
7
Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.转移性乳腺癌患者肿瘤标志物水平随肿瘤亚型的变化。
J BUON. 2013 Jul-Sep;18(3):608-13.
8
Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer.癌胚抗原(CEA)和糖类抗原15-3(CA 15-3)在乳腺癌中的长期预后研究
Int J Clin Oncol. 2008 Oct;13(5):447-51. doi: 10.1007/s10147-008-0773-3. Epub 2008 Oct 23.
9
Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).血清细胞角蛋白片段21.1(CYFRA 21.1)作为乳腺癌肿瘤标志物:与糖类抗原15.3(CA 15.3)和癌胚抗原(CEA)的比较
Clin Chem Lab Med. 2002 Mar;40(3):298-303. doi: 10.1515/CCLM.2002.047.
10
[CEA and early detection of relapse in breast cancer subtypes: Comparison with CA 15-3].[癌胚抗原与乳腺癌亚型复发的早期检测:与糖类抗原15-3的比较]
Bull Cancer. 2016 May;103(5):434-43. doi: 10.1016/j.bulcan.2016.02.003. Epub 2016 Mar 8.

引用本文的文献

1
Utility of CA-125 for diagnosis and prognosis of breast cancer: a systematic review.CA-125在乳腺癌诊断和预后中的应用:一项系统评价。
Explor Target Antitumor Ther. 2025 May 15;6:1002316. doi: 10.37349/etat.2025.1002316. eCollection 2025.
2
The Effects of Preoperative Serum Carcinoembryonic Antigen, Cancer Antigen 15-3 and Cancer Antigen 125 on the Prognosis of Breast Cancer Patients With Different Molecular Subtypes.术前血清癌胚抗原、癌抗原15-3和癌抗原125对不同分子亚型乳腺癌患者预后的影响
J Clin Med Res. 2024 Oct;16(10):491-502. doi: 10.14740/jocmr5237. Epub 2024 Oct 16.
3
Risk-stratified CA125 screening integrating CA125 trajectories, trajectory-specific progression and transvaginal ultrasound for ovarian cancer.
基于 CA125 轨迹、轨迹特异性进展和经阴道超声的卵巢癌风险分层 CA125 筛查。
J Ovarian Res. 2024 Oct 26;17(1):210. doi: 10.1186/s13048-024-01535-9.
4
Enhancing electrochemical detection through machine learning-driven prediction for canine mammary tumor biomarker with green silver nanoparticles.通过机器学习驱动的预测来增强电化学检测,用于犬乳腺肿瘤生物标志物的绿色银纳米粒子。
Anal Bioanal Chem. 2024 Sep;416(23):5071-5088. doi: 10.1007/s00216-024-05444-0. Epub 2024 Jul 20.
5
Tumor-derived extracellular vesicles as a biomarker for breast cancer diagnosis and metastasis monitoring.肿瘤衍生的细胞外囊泡作为乳腺癌诊断和转移监测的生物标志物
iScience. 2024 Mar 14;27(4):109506. doi: 10.1016/j.isci.2024.109506. eCollection 2024 Apr 19.
6
Liquid biopsy utilizing miRNA in patients with advanced breast cancer treated with cyclin‑dependent kinase 4/6 inhibitors.在接受细胞周期蛋白依赖性激酶4/6抑制剂治疗的晚期乳腺癌患者中利用微小RNA进行液体活检。
Oncol Lett. 2024 Feb 28;27(4):181. doi: 10.3892/ol.2024.14314. eCollection 2024 Apr.
7
Exploring the Prognostic Value of CS15-3 Tumor Marker in Breast Cancer Recurrence.探讨 CS15-3 肿瘤标志物在乳腺癌复发中的预后价值。
Asian Pac J Cancer Prev. 2024 Jan 1;25(1):229-232. doi: 10.31557/APJCP.2024.25.1.229.
8
lowered serum carcinoembryonic antigen and antigen 125 in 7,12-Dimethylbenz[]anthracene-induced Mammary Carcinogenesis in Female Albino Rats.7,12-二甲基苯并[a]蒽诱导雌性白化大鼠乳腺癌发生过程中血清癌胚抗原和癌抗原125水平降低
Heliyon. 2023 Dec 5;10(1):e23401. doi: 10.1016/j.heliyon.2023.e23401. eCollection 2024 Jan 15.
9
Understanding crosstalk of organ tropism, tumor microenvironment and noncoding RNAs in breast cancer metastasis.解析乳腺癌转移中器官趋向性、肿瘤微环境和非编码 RNA 的串扰。
Mol Biol Rep. 2023 Nov;50(11):9601-9623. doi: 10.1007/s11033-023-08852-0. Epub 2023 Oct 4.
10
Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study.一项前瞻性观察研究显示,血清免疫肿瘤标志物为新诊断转移性乳腺癌患者提供了独立的预后信息。
Breast Cancer Res. 2023 Mar 21;25(1):29. doi: 10.1186/s13058-023-01631-6.